United States

Teva Pharmaceutical Industries Ltd (TEVA.K)

TEVA.K on New York Consolidated

22 Sep 2017
Change (% chg)

$0.04 (+0.23%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Get access to over 18 million research reports from over 1,700 sources.

For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.

Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.

Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:

  • ownership
  • filings
  • deals
  • private equity
  • third-party document and information retrieval
  • estimates
  • fundamentals
  • economics
  • events
  • news
  • and much, much more…

Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.

Name Age Since Current Position

Sol Barer

70 2017 Chairman of the Board

Yitzhak Peterburg

66 2017 Interim President and Chief Executive Officer

Kaare Schultz

56 President, Chief Executive Officer

Eyal Desheh

65 2014 Group Executive Vice President, Chief Financial Officer

Dipankar Bhattacharjee

56 2016 President and Chief Executive Officer-Global Generic Medicines Group